University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.

Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.

UW Carbone Cancer Center will begin treating adults with a “living drug” that employs their own immune cells to fight a common type of aggressive blood cancer.

Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses combinations in multiple myeloma.

According to a new study by UW Carbone Cancer Center researchers, a broadly applicable cancer therapy currently being developed by Cellectar Biosciences may have the potential to work in pediatric solid tumors.

PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.

Mark Burkard, MD, PhD, discusses the steps researchers are taking to address questions on genomics in breast cancer and what subtypes pose the greatest challenges.

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

A brain tumor research group at the UW Carbone Cancer Center focuses on biological studies of patient-derived glioblastoma multiforme (GBM) cancer stem cells, combined with analysis of patient-matched serum-cultured GBM and an annotated GBM tissue microarray, to identify clinically relevant biomarkers.

Researchers at the University of Wisconsin School of Medicine and Public Health have found that removing a specific type of collagen can dramatically reduce the growth of one form of breast cancer.

In a large-scale study published today in the journal Obstetrics and Gynecology, researchers found that nearly half of women from racial minorities receive cervical-cancer care that doesn’t meet national standards.

Half of the patients in a Wisconsin Oncology Network (WON) clinical trial for a rare blood cancer are still in remission eight years after beginning treatment, according to new results of a follow-up to the study.

A new clinical trial for women with clinically aggressive triple-negative breast cancer (TNBC) will test a novel theory: Will a diet low in an essential nutrient make TNBC cells more vulnerable to cell killing by a new cancer drug?

The major advance of the MRI-guided radiotherapy system is the ability to visualize the lumpectomy cavity before and during the delivery of each treatment.

An international leader in harnessing a patient's own stem cells to fight cancer and autoimmune diseases joined the faculty of the University of Wisconsin Carbone Cancer Center on September 1.

This pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.

Finding is relevant to certain cancers of the blood.

Despite advances, the majority of patients receiving targeted therapies do not experience radiographic responses, and nearly all patients who initially benefit develop resistance in less than two years.

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

Preclinical mouse models and cell lines link colorectal cancer subtypes subtypes with potential therapies.

Focus will be on Wisconsin Center's innovative research centers and impact on local communities.

Stephen Rosenberg, MD, University of Wisconsin School of Medicine and Public Health, discusses a study examining if online patient information provided by National Cancer Institute (NCI)-designated cancer center websites is too complex for general readership.

Ruth M. O'Regan, MD, discusses two of her studies in HER2-positive breast cancer presented at ASCO 2015.

Ruth O'Regan, MD, medical oncology, Breast Cancer Clinic, University of Wisconsin Carbone Cancer Center, faculty, University of Wisconsin School of Medicine and Public Health, evaluates the Breast Cancer Index in patients with HER2-positive, HR-positive breast cancer for risk of late recurrence and endocrine benefit.

Currently, more than 250 physicians and scientists work in concert to provide state-of- the art diagnosis, treatment, and aftercare for the more than 20,000 patients seen each year at the UW hospitals, clinics, and affiliate clinical facilities